Recalcitrant Atopic Dermatitis Treated with Omalizumab
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Atopic dermatitis (AD) is a chronic cutaneous inflammatory disease. Various categories of therapeutic medications are used for treating AD. Omalizumab is a monoclonal anti-IgE antibody that binds to IgE molecules at the high-affinity receptor (FcεRI) binding site. Therefore, omalizumab can be used as a potential new systemic treatment agent for recalcitrant AD patients with elevated IgE levels. A 34-year-old man had been treated for AD with several topical and oral agents. However, he was refractory to these therapies and his serum IgE levels were very high. We treated him with omalizumab. After 8 months of the treatment, his symptoms were notably improved and the SCORAD index was decreased. Thus, we report on the first case of recalcitrant AD that was successfully treated with omalizumab in Korea. (Ann Dermatol 22(3) 349∼352,2010)
Abstract
Atopic dermatitis (AD) is a chronic cutaneous inflammatory disease. Various categories of therapeutic medications are used for treating AD. Omalizumab is a monoclonal anti-IgE antibody that binds to IgE molecules at the high-affinity receptor (FcεRI) binding site. Therefore, omalizumab can be used as a potential new systemic treatment agent for recalcitrant AD patients with elevated IgE levels. A 34-year-old man had been treated for AD with several topical and oral agents. However, he was refractory to these therapies and his serum IgE levels were very high. We treated him with omalizumab. After 8 months of the treatment, his symptoms were notably improved and the SCORAD index was decreased. Thus, we report on the first case of recalcitrant AD that was successfully treated with omalizumab in Korea. (Ann Dermatol 22(3) 349∼352,2010)
참고문헌 (13)
- Akdis CA, "Diagnosis and treatment of atopic dermatitis in children and adults:European Academy of Allergology and Clinical Immunology", American Academy of Allergy,Asthma and Immunology, J Allergy Clin Immunol, pp.2006, 118[DOI]
- 이보현, "Dapsone에 호전을 보인 난치성 아토피 피부염 1예", 대한피부과학회지, 43(12), pp.1626~1630 (2005), 대한피부과학회
- Kuanprasert N, "Clinical improvement and significant reduction of total serum IgE in patients suffering from severe atopic dermatitis treated with oral azathioprine", Australas J Dermatol, 43, pp.125~127 (2002)
- Neuber K, "Treatment of atopic eczema with oral mycophenolate mofetil", Br J Dermatol, 143, pp.385~391 (2000)
- Jolles S, "The treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin:a report of three patients and review of the literature", Br J Dermatol, 142, pp.551~554 (2000)
- Krathen RA, "Failure of omalizumab for treatment of severe adult atopic dermatitis", J Am Acad Dermatol, 53, pp.338~340 (2005)
- Bieber T, "Atopic dermatitis", N Engl J Med, 358, pp.1483~1494 (2008)
- Stingl G, "IgE-mediated, Fc(epsilon)RI-dependent allergen presentation: a pathogenetic factor in atopic dermatitis?", J Am Acad Dermatol, 45, pp.S17~S20 (2001)
- Lane JE, "Treatment of recalcitrant atopic dermatitis with omalizumab", J Am Acad Dermatol, 54, pp.68~72 (2006)
- Lowe PJ, "Relationship between omalizumab pharmacokinetics,IgE pharmacodynamics and symptoms in patients with severe persistent allergic(IgE-mediated)asthma", Br J Clin Pharmacol, 68, pp.61~76 (2009)
- Salvin RG, "Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentration", J Allergy Clin Immunol, 123, pp.107~113 (2009)
- Vigo PG, "Efficacy of anti-IgE therapy in patients with atopic dermatitis", J Am Acad Dermatol, 55, pp.168~170 (2006)
- Nowak D, "Management of asthma with anti-immunoglobulin E:A review of clinical trials of omalizumab", Respir Med, 100, pp.1907~1917 (2006)